Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels

Blood

Volumn 126, Issue 26, 2015, Pages 2896-2899

  Mullighan, Charles G ^a   Jeha, Sima ^a   Pei, Deqing ^a   Payne Turner, Debbie ^a   Coustan Smith, Elaine ^b   Roberts, Kathryn G ^a   Waanders, Esmé ^c   Choi, John K ^a   Ma, Xiaotu ^a   Raimondi, Susana C ^a   Fan, Yiping ^a   Yang, Wenjian ^a   Song, Guangchun ^a   Yang, Jun J ^a   Inaba, Hiroto ^a   Downing, James R ^a   Leung, Wing H ^a   Bowman, W Paul ^d   Relling, Mary V ^a   Evans, William E ^a   Zhang, Jinghui ^a   Campana, Dario ^b   Pui, Ching Hon ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d University of North Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOTRANSPLANTATION; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; GENE EXPRESSION; HAPLOIDY; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; CHILD; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; MALE; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84955299724     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-671131     Document Type: Letter

References (21)

1. Pui CH, Williams DL, Raimondi SC, et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1987;70(1): 247-253.
2. Pui CH, Carroll AJ, Raimondi SC, et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood. 1990;75(5): 1170-1177.
3. Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood. 1999;94(12):4036-4045.
4. Raimondi SC, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer. 2003;98(12):2715-2722.
5. Harrison CJ, Moorman AV, Broadfield ZJ, et al; Childhood and Adult Leukaemia Working Parties. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004;125(5):552-559.
6. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110(4):1112-1115.
7. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242-252.
8. Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progressive through collaboration. J Clin Oncol. 2015;33(27):2938-2948.
9. Schultz KR, Devidas M, Bowman WP, et al; Children's Oncology Group. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. Leukemia. 2014;28(4):964-967.
10. Oliansky DM, Camitta B, Gaynon P, et al; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012;18(4):505-522.
11. Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16(4):465-474.
12. Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCRABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27): 3012-3020.
13. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
14. Pui CH, Campana D, Sandlund JT, et al. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. Ann Hematol. 2011; 90(suppl 1):S61-S63.
15. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8): 2691-2696.
16. Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115(23):4657-4663.
17. Pounds S, Cheng C, Mullighan C, Raimondi SC, Shurtleff S, Downing JR. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics. 2009;25(3):315-321.
18. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657-663.
19. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
20. Mullighan CG, Su X, Zhang J, et al; Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-480.
21. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11): 1005-1015.